Matches in SemOpenAlex for { <https://semopenalex.org/work/W2002605588> ?p ?o ?g. }
- W2002605588 endingPage "525" @default.
- W2002605588 startingPage "522" @default.
- W2002605588 abstract "Abstract Although the combination of lenalidomide and dexamethasone is effective therapy for patients with relapsed/refractory multiple myeloma, the influence of high-risk cytogenetic abnormalities on outcomes is unknown. This subanalysis of a large, open-label study investigated the effects of the most common unfavorable cytogenetic abnormalities detected by fluorescence in situ hybridization, del(13q), t(4;14), and del(17p13), in 130 evaluable patients treated with this regimen. Whereas patients with either del(13q) or t(4;14) experienced a median time to progression and overall survival comparable with those without these cytogenetic abnormalities, patients with del(17p13) had a significantly worse outcome, with a median time to progression of 2.22 months (hazard ratio, 2.82; P < .001) and median overall survival of 4.67 months (hazard ratio, 3.23; P < .001). Improved therapeutic strategies are required for this subgroup of patients. This study was registered at www.ClinicalTrials.gov as #NCT00179647." @default.
- W2002605588 created "2016-06-24" @default.
- W2002605588 creator A5003338851 @default.
- W2002605588 creator A5003741023 @default.
- W2002605588 creator A5009025511 @default.
- W2002605588 creator A5018664175 @default.
- W2002605588 creator A5022374560 @default.
- W2002605588 creator A5033710140 @default.
- W2002605588 creator A5038365893 @default.
- W2002605588 creator A5043490010 @default.
- W2002605588 creator A5054254800 @default.
- W2002605588 creator A5059894379 @default.
- W2002605588 creator A5065238694 @default.
- W2002605588 creator A5068947490 @default.
- W2002605588 creator A5086115833 @default.
- W2002605588 date "2009-07-16" @default.
- W2002605588 modified "2023-10-06" @default.
- W2002605588 title "Influence of cytogenetics in patients with relapsed or refractory multiple myeloma treated with lenalidomide plus dexamethasone: adverse effect of deletion 17p13" @default.
- W2002605588 cites W1978377409 @default.
- W2002605588 cites W1992538067 @default.
- W2002605588 cites W1993272300 @default.
- W2002605588 cites W1994721812 @default.
- W2002605588 cites W1995576598 @default.
- W2002605588 cites W2011644923 @default.
- W2002605588 cites W2011871138 @default.
- W2002605588 cites W2019948899 @default.
- W2002605588 cites W2021954218 @default.
- W2002605588 cites W2044436186 @default.
- W2002605588 cites W2065859796 @default.
- W2002605588 cites W2066800926 @default.
- W2002605588 cites W2087843841 @default.
- W2002605588 cites W2093757149 @default.
- W2002605588 cites W2096207943 @default.
- W2002605588 cites W2097676652 @default.
- W2002605588 cites W2097752354 @default.
- W2002605588 cites W2104452168 @default.
- W2002605588 cites W2127096655 @default.
- W2002605588 cites W2136373453 @default.
- W2002605588 cites W2143756652 @default.
- W2002605588 cites W2565680360 @default.
- W2002605588 cites W52949034 @default.
- W2002605588 doi "https://doi.org/10.1182/blood-2008-12-193458" @default.
- W2002605588 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/19332768" @default.
- W2002605588 hasPublicationYear "2009" @default.
- W2002605588 type Work @default.
- W2002605588 sameAs 2002605588 @default.
- W2002605588 citedByCount "179" @default.
- W2002605588 countsByYear W20026055882012 @default.
- W2002605588 countsByYear W20026055882013 @default.
- W2002605588 countsByYear W20026055882014 @default.
- W2002605588 countsByYear W20026055882015 @default.
- W2002605588 countsByYear W20026055882016 @default.
- W2002605588 countsByYear W20026055882017 @default.
- W2002605588 countsByYear W20026055882018 @default.
- W2002605588 countsByYear W20026055882019 @default.
- W2002605588 countsByYear W20026055882020 @default.
- W2002605588 countsByYear W20026055882021 @default.
- W2002605588 countsByYear W20026055882022 @default.
- W2002605588 countsByYear W20026055882023 @default.
- W2002605588 crossrefType "journal-article" @default.
- W2002605588 hasAuthorship W2002605588A5003338851 @default.
- W2002605588 hasAuthorship W2002605588A5003741023 @default.
- W2002605588 hasAuthorship W2002605588A5009025511 @default.
- W2002605588 hasAuthorship W2002605588A5018664175 @default.
- W2002605588 hasAuthorship W2002605588A5022374560 @default.
- W2002605588 hasAuthorship W2002605588A5033710140 @default.
- W2002605588 hasAuthorship W2002605588A5038365893 @default.
- W2002605588 hasAuthorship W2002605588A5043490010 @default.
- W2002605588 hasAuthorship W2002605588A5054254800 @default.
- W2002605588 hasAuthorship W2002605588A5059894379 @default.
- W2002605588 hasAuthorship W2002605588A5065238694 @default.
- W2002605588 hasAuthorship W2002605588A5068947490 @default.
- W2002605588 hasAuthorship W2002605588A5086115833 @default.
- W2002605588 hasConcept C104317684 @default.
- W2002605588 hasConcept C126322002 @default.
- W2002605588 hasConcept C142424586 @default.
- W2002605588 hasConcept C143998085 @default.
- W2002605588 hasConcept C174475383 @default.
- W2002605588 hasConcept C197934379 @default.
- W2002605588 hasConcept C207103383 @default.
- W2002605588 hasConcept C2776063141 @default.
- W2002605588 hasConcept C2776364478 @default.
- W2002605588 hasConcept C2777542201 @default.
- W2002605588 hasConcept C2779609412 @default.
- W2002605588 hasConcept C2780401358 @default.
- W2002605588 hasConcept C2781413609 @default.
- W2002605588 hasConcept C30481170 @default.
- W2002605588 hasConcept C44249647 @default.
- W2002605588 hasConcept C55493867 @default.
- W2002605588 hasConcept C71924100 @default.
- W2002605588 hasConcept C86803240 @default.
- W2002605588 hasConcept C87355193 @default.
- W2002605588 hasConcept C90924648 @default.
- W2002605588 hasConceptScore W2002605588C104317684 @default.
- W2002605588 hasConceptScore W2002605588C126322002 @default.
- W2002605588 hasConceptScore W2002605588C142424586 @default.
- W2002605588 hasConceptScore W2002605588C143998085 @default.
- W2002605588 hasConceptScore W2002605588C174475383 @default.